Non-Melanoma Skin Cancer

World Market Report

MCP13619

EXECUTIVE ENGAGEMENTS

POOL

612
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

122
Interactions with Platform & by Email

PARTICIPANTS

24
Unique # Participated

VALIDATIONS

12
Responses Validated*

COMPANIES

46
Responses Validated*
* Login for a full stack data experience

DATE

OCT 2022

TABLES

123

PAGES

196

EDITION

6

PRICE

USD 4950

CODE

MCP13619


COMPETITIVE METRICS

COMPETITORS (ALPHABETICAL)

STRONG ACTIVE NICHE TRIVIAL

%

VALIDATED RESEARCH *

S A N T
S A N T

* S = Strong; A = Active; N = Niche; T= Trivial (<1%)
* Login to Participate & View Data Stacks
* Participating executives must be from a competitive company. Executive credentials are validated by a one-time two-factor authentication, in compliance with GDPR guidelines. Verified executives have complimentary access to our proprietary MarketGlassTM platform and relevant data silos including Trend Data; Brand/IP/TM Feeds; and Market Size, Share & Rank Clusters. Qualified influencers are also invited to join our Expert Panels. Privileges include purchase credits, and collaborative bespoke builds.
View All Companies...

PARTICIPATE NOW!
RESEARCH MODULES EXECUTIVES
  

HIGHLIGHTS & REPORT INDEX

What`s New for 2022?

» Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
» Online interactive peer-to-peer collaborative bespoke updates
» Access to our digital archives and MarketGlass Research Platform
» Complimentary updates for one year

Amid the COVID-19 crisis, the global market for Non-Melanoma Skin Cancer estimated at US$585.4 Million in the year 2020, is projected to reach a revised size of US$791.1 Million by 2027, growing at aCAGR of 4.4% over the period 2020-2027. Basal Cell Carcinoma (BCC), one of the segments analyzed in the report, is projected to record 4.7% CAGR and reach US$639 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Other Indications segment is readjusted to a revised 3.3% CAGR for the next 7-year period.
The Non-Melanoma Skin Cancer market in the U.S. is estimated at US$172.4 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$139.9 Million by the year 2027 trailing a CAGR of 4.1% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.3% and 3.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

SELECT PLAYERS

Accuray, Inc.; Almirall S.A.; Boehringer Ingelheim GmbH; Bristol-Myers Squibb Company; Elekta AB; Eli Lilly and Company; F. Hoffmann-La Roche Ltd.; iCAD, Inc.; Ion Beam Applications SA; Merck & Co., Inc.; Mylan NV; Novartis AG; Sensus Healthcare; Sun Pharmaceutical Industries Ltd.; Varian Medical Systems, Inc.

SEGMENTS

» Indication (Basal Cell Carcinoma (BCC), Other Indications) » Treatment Type (Radiation Therapy, Other Treatment Types)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Non-melanoma Skin Cancer – Global Key Competitors Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
World Non-Melanoma Skin Cancer Market Analysis of Annual Sales in US$ Thousand for Years 2012 through 2027
World Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Non-Melanoma Skin Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Non-Melanoma Skin Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Basal Cell Carcinoma (BCC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Basal Cell Carcinoma (BCC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Basal Cell Carcinoma (BCC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Radiation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Other Treatment Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
UNITED STATES
Non-Melanoma Skin Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
USA Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
USA Historic Review for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Non-Melanoma Skin Cancer by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Other Indications for the Years 2012, 2021 & 2027
USA Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
USA Historic Review for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Non-Melanoma Skin Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
CANADA
Canada Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Non-Melanoma Skin Cancer by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Other Indications for the Years 2012, 2021 & 2027
Canada Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Non-Melanoma Skin Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
JAPAN
Non-Melanoma Skin Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
Japan Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Non-Melanoma Skin Cancer by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Other Indications for the Years 2012, 2021 & 2027
Japan Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Non-Melanoma Skin Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
CHINA
Non-Melanoma Skin Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)
China Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
China Historic Review for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Non-Melanoma Skin Cancer by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Other Indications for the Years 2012, 2021 & 2027
China Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
China Historic Review for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Non-Melanoma Skin Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
EUROPE
Non-Melanoma Skin Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
Europe Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Europe Historic Review for Non-Melanoma Skin Cancer by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Non-Melanoma Skin Cancer by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2021 & 2027
Europe Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Non-Melanoma Skin Cancer by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Other Indications for the Years 2012, 2021 & 2027
Europe Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Non-Melanoma Skin Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
FRANCE
Non-Melanoma Skin Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)
France Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
France Historic Review for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Non-Melanoma Skin Cancer by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Other Indications for the Years 2012, 2021 & 2027
France Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
France Historic Review for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Non-Melanoma Skin Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
GERMANY
Non-Melanoma Skin Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)
Germany Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Non-Melanoma Skin Cancer by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Other Indications for the Years 2012, 2021 & 2027
Germany Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Non-Melanoma Skin Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
ITALY
Italy Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Non-Melanoma Skin Cancer by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Other Indications for the Years 2012, 2021 & 2027
Italy Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Non-Melanoma Skin Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
UNITED KINGDOM
Non-Melanoma Skin Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)
UK Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UK Historic Review for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Non-Melanoma Skin Cancer by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Other Indications for the Years 2012, 2021 & 2027
UK Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UK Historic Review for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Non-Melanoma Skin Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
REST OF EUROPE
Rest of Europe Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Non-Melanoma Skin Cancer by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Other Indications for the Years 2012, 2021 & 2027
Rest of Europe Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Non-Melanoma Skin Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
ASIA-PACIFIC
Non-Melanoma Skin Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
Asia-Pacific Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Non-Melanoma Skin Cancer by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Other Indications for the Years 2012, 2021 & 2027
Asia-Pacific Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Non-Melanoma Skin Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatment Types for the Years 2012, 2021 & 2027
REST OF WORLD
Rest of World Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Non-Melanoma Skin Cancer by Indication - Basal Cell Carcinoma (BCC) and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Non-Melanoma Skin Cancer by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma (BCC) and Other Indications for the Years 2012, 2021 & 2027
Rest of World Recent Past, Current & Future Analysis for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Non-Melanoma Skin Cancer by Treatment Type - Radiation Therapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Non-Melanoma Skin Cancer by Treatment Type - Percentage Breakdown of Value Sales for Radiation Therapy and Other Treatment Types for the Years 2012, 2021 & 2027

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com